Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency

[1]  M. Fakih,et al.  Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity , 2016, Cancer.

[2]  F. Nugent,et al.  Early‐Onset 5‐Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate , 2016, Pharmacotherapy.

[3]  K. Vistisen,et al.  Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer , 2016, BMJ Open.

[4]  Sarah E. Dorff,et al.  FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs , 2016, Clinical Cancer Research.

[5]  J. Schellens,et al.  Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. , 2016, European journal of cancer.

[6]  U. Amstutz,et al.  Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity , 2014, International journal of cancer.

[7]  Kirsten Vistisen,et al.  Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. , 2013, Cancer treatment reviews.

[8]  O. N. Al Safarjalani,et al.  Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity , 2012, Cancer Chemotherapy and Pharmacology.

[9]  M. Bamat,et al.  Point-of-care (POC) diagnostic assay for 5-fluorouracil (5-FU) quantitation to enable dose adjustment and detect dihydropyrimidine dehydrogenase (DPD) deficiency. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Iliadis,et al.  Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile , 2009, Cancer Chemotherapy and Pharmacology.

[11]  J. Doroshow,et al.  Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study , 2006, Investigational New Drugs.

[12]  W. Ichikawa,et al.  Orotate Phosphoribosyltransferase Gene Polymorphism Predicts Toxicity in Patients Treated with Bolus 5-Fluorouracil Regimen , 2006, Clinical Cancer Research.

[13]  R. Schinazi,et al.  Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor , 2006, Cancer Chemotherapy and Pharmacology.

[14]  M. Saif,et al.  5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice , 2006, Cancer Chemotherapy and Pharmacology.

[15]  R. Diasio,et al.  Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. , 2004, Clinical colorectal cancer.

[16]  S. Spiegelman,et al.  Effect of Uridine on the Metabolism of 5-Fluorouracil in the CD8F1 Murine Mammary Carcinoma System , 1984, Pharmaceutical Research.

[17]  D. Martin,et al.  Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine , 2004, Cancer Chemotherapy and Pharmacology.

[18]  R. Cysyk,et al.  Comparison of the bioavailability of uridine in mice after either oral or parenteral administration , 2004, Cancer Chemotherapy and Pharmacology.

[19]  D. Perrier,et al.  Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients , 2004, European Journal of Clinical Pharmacology.

[20]  J. Baars,et al.  Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  G. Peters,et al.  High-Dose 5-Fluorouracil with Uridine-Diphosphoglucose Rescue Increases Thymidylate Synthase Inhibition but Not 5-Fluorouracil Incorporation into RNA in Murine Tumors , 2002, Oncology.

[22]  R. Bright,et al.  Process Research and Development of a Dihydropyrimidine Dehydrogenase Inactivator: Large-Scale Preparation of Eniluracil Using a Sonogashira Coupling , 2001 .

[23]  F. Baas,et al.  Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  O. Ashour,et al.  Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine. , 2000, Biochemical pharmacology.

[25]  J. Bertino,et al.  Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Potten,et al.  Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Peters,et al.  Modulation of 5-fluorouracil in mice using uridine diphosphoglucose. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  K. Yeh,et al.  High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. , 1997, British Journal of Cancer.

[29]  O. Ashour,et al.  5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy. , 1996, Biochemical pharmacology.

[30]  D. Baccanari,et al.  5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Martin,et al.  Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA. , 1992, Biochemical pharmacology.

[32]  G. Peters,et al.  Clinical and pharmacologic study of orally administered uridine. , 1991, Journal of the National Cancer Institute.

[33]  Y. Yoshikai,et al.  Induction of lethal infection with indigenous Escherichia coli in mice by fluorouracil. , 1991, Canadian journal of microbiology.

[34]  G. Peters,et al.  Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. , 1988, Cancer research.

[35]  G. Peters,et al.  In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil. , 1988, British Journal of Cancer.

[36]  S. Spiegelman,et al.  Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue. , 1983, Cancer research.

[37]  P. Klubes,et al.  Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. , 1983, Cancer research.

[38]  S. Spiegelman,et al.  High-dose 5-fluorouracil with delayed uridine "rescue" in mice. , 1982, Cancer research.

[39]  S. Imai,et al.  Cardiotoxic effects of 5-fluorouracil in the guinea pig. , 1980, Japanese journal of pharmacology.

[40]  Harrison Sd,et al.  Qualitative and quantitative toxicity of single and sequential sublethal doses of 5-fluorouracil in BDF mice. , 1978 .

[41]  E. P. Denine,et al.  Qualitative and quantitative toxicity of single and sequential sublethal doses of 5-fluorouracil in BDF mice. , 1978, Cancer treatment reports.